Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Baseline Comorbidities and Changes in Acute Medication Use by Quarterly and Monthly Dosing Regimen in Patients Prescribed AJOVY in US Physician Practices
Headache
Headache Posters (7:00 AM-5:00 PM)
122

AJOVY (fremanezumab), a fully-humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), has been approved for preventive migraine treatment in adults.

The objective of this real-world, retrospective, observational study was to assess baseline comorbidities and changes in acute medication use among patients prescribed quarterly and monthly AJOVY.

Data were obtained from the Veradigm Health Insights Database (AllScripts and Practice Fusion Electronic Health Records Databases). The study period was January 1, 2014–June 30, 2019. Patients were included if they were ≥18 years; had ≥1 migraine diagnosis during the study period; and had a medication record for AJOVY on or after diagnosis during the identification period (September 1, 2018–December 31, 2018). Patients were excluded if they had missing/unknown age or gender information, prescription record for any CGRP pathway-targeted therapy prior to the index date, or evidence of pregnancy/childbirth during the study.

186 (18.8%) and 801 (81.2%) patients were prescribed quarterly and monthly AJOVY, respectively. With quarterly and monthly AJOVY, respectively, the most common comorbidities were depression (17% and 14%), anxiety disorders (16% and 15%), hypertension (13% and 11%), back pain (11% and 12%), high cholesterol (12% and 12%), neck pain (13% and 10%), insomnia (14% and 9%), and allergies (10% and 9%). Prior to initiating AJOVY, patients prescribed monthly dosing were more likely to be prescribed acute medications (40.2% vs quarterly, 31.2%, P=0.0228), especially triptans (39.2% vs 30.1%, P=0.0210). After initiating quarterly and monthly AJOVY, respectively, 36% and 43% discontinued (>45-day gap) acute medications, including triptans (19% and 23%), ergots (1% and 1%), nonsteroidal anti-inflammatory drugs (12% and 14%), and opioids (7% and 11%).

This real-world study showed that comorbidities at baseline were comparable for patients with quarterly and monthly dosing. Patients on quarterly AJOVY were less likely to be prescribed acute medications.

Authors/Disclosures
Lynda Krasenbaum
PRESENTER
Lynda Krasenbaum has received personal compensation for serving as an employee of Teva Pharmaceuticals.
Stephen F. Thompson Stephen Thompson has received personal compensation for serving as an employee of Teva Pharmaceuticals.
Joshua M. Cohen, MD No disclosure on file
Krishna Tangirala (Teva ;Pharmaceuticals) Krishna Tangirala has received personal compensation for serving as an employee of Teva Pharmaceuticals.
Chien-Cheng Chen Chien-Cheng Chen has received personal compensation for serving as an employee of StatInMed.
Deborah Freedman No disclosure on file